Home Transfusion for HEME

Save

Report Abuse

Description

The purpose of the research is to assess the feasibility and acceptability of a home blood transfusion program for patients with hematologic malignancies who need blood transfusions

Targeted Conditions

Study Overview

Start Date
April 30, 2024
Completion Date
March 31, 2025
Enrollment
20
Date Posted
August 22, 2022
Accepts Healthy Volunteers?
Yes
Gender
All

Locations

Full Address
Dana-Farber Cancer Institute
Boston, Massachusetts 02215, United States

Eligibility

Minimum Age (years)
18
Eligibility Criteria
Inclusion Criteria:

Patients with advanced hematologic malignancies:

Diagnosis of a hematologic malignancy
Age ≥ 18 years
Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment)
Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a serious adverse transfusion reaction
Physician-estimated prognosis of six months or less
Has an adult informal caregiver that lives in the same residence
Patient resides within catchment served by Care Dimensions Hospice

Caregivers:

Identified informal caregiver of enrolled patient with hematologic malignancy
Age ≥ 18 years

Exclusion Criteria:

Patients

Age < 18 years
Does not have an identified adult informal caregiver who lives in the same residence
History of previous serious adverse transfusion reaction
Presence of decompensated congestive heart failure

Caregiver

Age < 18 years

Our study will exclude members of the following special populations:

Adults unable to consent
Individuals who are not yet adults (infants, children, teenagers)
Pregnant women
Prisoners

Study Contact Info

Study Contact Name
Oreofe O. Odejide, MD,MPH
Study Contact Email
Study Contact Phone

Contact Listings Owner Form

Home Transfusion for HEME 0 reviews

Write Your Review

There are no reviews yet.

Write Your Review

Your email address will not be published. Required fields are marked *

Other Details

FDA Regulated Drug?
No
FDA Regulated Device?
No
Detailed Description
This feasibility study will be used to assess the feasibility and acceptability of a hospice-embedded home transfusion program to patients with hematologic malignancies. All enrolled subjects will be patients cared for at Dana Farber Cancer Institute.

This study is a single-arm study of 10 patients with advanced hematologic malignancies who have a limited life-expectancy of six months or fewer and are hospice eligible.

10 Caregivers of enrolled patients will also be invited to participate if interested.

This research study involves completing questionnaires, a brief interview, blood draws, and blood transfusions when needed.

Participants will be in the research study for up to six months.

It is expected that about 20 people will take part in this research study.
NCTid (if applicable)
NCT05509439